{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:42:41Z","timestamp":1787578961656,"version":"build-2736575974"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Severe acute respiratory syndrome corona virus 2 (SARS CoV-2) is the cause of Corona virus disease 2019 (COVID-19), which turned into a pandemic in late 2019 and early 2020. SARS CoV-2 causes endothelial cell destruction and swelling, microthrombosis, constriction of capillaries, and malfunction of pericytes, all of which are detrimental to capillary integrity, angiogenesis, and healing processes. Cytokine storming has been connected to COVID-19 disease. Hypoxemia and tissue hypoxia may arise from impaired oxygen diffusion exchange in the lungs due to capillary damage and congestion. This personal view will look at how inflammation and capillary damage affect blood and tissue oxygenation, cognitive function, and the duration and intensity of COVID-19 disease. The general effects of microvascular injury, hypoxia, and capillary damage caused by COVID-19 in key organs are also covered in this point of view. Once initiated, this vicious cycle leads to diminished capillary function, which exacerbates inflammation and tissue damage, and increased inflammation due to hypoxia. Brain damage may result from low oxygen levels and high cytokines in brain tissue. In this paper we give a summary in this direction with focus on the role of the neuropeptide Substance P. On the basis of this, we discuss selected approaches to the question: \u201cHow Substance P is involved in the etiology of the COVID-19 and how results of our research could improve the prevention or therapy of corona? Thereby pointing out the role of Substance P in the post-corona syndrome and providing novel concepts for therapy and prevention.<\/jats:p>","DOI":"10.3389\/fneur.2024.1370454","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:49:24Z","timestamp":1717044564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Substance P \u2013 a regulatory peptide with defense and repair functions. Results and perspectives for the fight against COVID-19"],"prefix":"10.3389","volume":"15","author":[{"given":"Riffat","family":"Mehboob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehreem","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Peter","family":"von Kries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1113\/jphysiol.1931.sp002763","article-title":"An unidentified depressor substance in certain tissue extracts","volume":"72","author":"Euler","year":"1931","journal-title":"J Physiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/newbio232086a0","article-title":"Amino-acid sequence of substance P","volume":"232","author":"Chang","year":"1971","journal-title":"Nat New Biol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.pupt.2017.12.001","article-title":"Neuropeptides and breathing in health and disease","volume":"48","author":"Kaczy\u0144ska","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1378\/chest.121.2.621","article-title":"Airway hyperresponsiveness and calcium handling by smooth muscle: a \u201cdeeper look\u201d","volume":"121","author":"Parameswaran","year":"2002","journal-title":"Chest"},{"key":"ref5","first-page":"843","article-title":"Vertebrate specific oncogenic TAC1 has unconventional networking properties","volume":"8","author":"Mehboob","year":"2014","journal-title":"HealthMED"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1016\/j.wneu.2019.08.064","article-title":"Persistently high serum substance P levels and early mortality in patients with severe traumatic brain injury","volume":"132","author":"Lorente","year":"2019","journal-title":"World Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fped.2018.00006","article-title":"Neurochemical alterations in sudden unexplained perinatal deaths\u2013a review","volume":"6","author":"Muhammad","year":"2018","journal-title":"Front Pediatr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fneur.2017.00320","article-title":"Towards better understanding of the pathogenesis of neuronal respiratory network in sudden perinatal death","volume":"8","author":"Mehboob","year":"2017","journal-title":"Front Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.prp.2014.09.016","article-title":"Role of neurotransmitter Substance P in progression of oral squamous cell carcinoma","volume":"211","author":"Mehboob","year":"2015","journal-title":"Pathol Res Pract"},{"key":"ref10","volume-title":"Nobel Sympoium 37","author":"Von Euler","year":"1977"},{"key":"ref11","first-page":"327","article-title":"Biological action of substance P\u2013its differentiation by affinity and intrinsic efficacy","volume":"1","author":"Oehme","year":"1977","journal-title":"Substance P"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.6154313","article-title":"Substance P: does it produce analgesia or hyperalgesia?","volume":"208","author":"Oehme","year":"1980","journal-title":"Science"},{"key":"ref13","author":"Goerne","year":"1982"},{"key":"ref14","first-page":"159","article-title":"Effect of Substance P analogue on chronic deprivation of sleep of Wistar rats under stress","volume-title":"Neuropeptides and neural transmission, International Brain Research Organization (IBRO)","author":"Hecht","year":"1980"},{"key":"ref15","first-page":"73","article-title":"Substance P as a modulator of physiological and pathological processes","volume-title":"Neuropeptides and neural transmission","author":"Oehme","year":"1980"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/0165-6147(83)90521-7","article-title":"Substance P: a peptide with unusual features","volume":"4","author":"Oehme","year":"1983","journal-title":"Trends Pharmacol Sci"},{"key":"ref17","first-page":"103","article-title":"Effect of substance P (SP) and the N-terminal SP-analogue SP (1-4) on the pre-and postsynaptic transmitter release in rat adrenal gland slices","volume":"46","author":"Nieber","year":"1987","journal-title":"Biomed Biochim Acta"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1113\/jphysiol.1983.sp014543","article-title":"Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin","volume":"335","author":"Foreman","year":"1983","journal-title":"J Physiol"},{"key":"ref19","first-page":"143","article-title":"Histaminfreisetzung aus Mastzellen Durch Substanz P","volume":"122","author":"Renner","year":"1983","journal-title":"Zentralbl Pharm"},{"key":"ref20","first-page":"90","article-title":"Rolle von Substanz P in der Regulation der Bronchomotorik und der Pathogenese der bronchialen Hyperreagibilit\u00e4t","volume":"172","author":"Schreiber","year":"1989","journal-title":"Z Erkr Atmungsorgane"},{"key":"ref21","first-page":"97","article-title":"Influence of capsaicin on the reagibility of the isolated guinea pig trachea","volume":"49","author":"Schreiber","year":"1990","journal-title":"Biomed Biochim Acta"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0167-0115(00)00177-4","article-title":"Principles of tachykininergic co-transmission in the peripheral and enteric nervous system","volume":"93","author":"Maggi","year":"2000","journal-title":"Regul Pept"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.peptides.2013.07.024","article-title":"Involvement of substance P and the NK-1 receptor in cancer progression","volume":"48","author":"Munoz","year":"2013","journal-title":"Peptides"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0014-2999(81)90384-8","article-title":"Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin","volume":"71","author":"Unger","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors","volume":"281","author":"Kramer","year":"1998","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0143-4179(98)90015-4","article-title":"The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles","volume":"32","author":"Quartara","year":"1998","journal-title":"Neuropeptides"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0304-3959(99)00240-7","article-title":"Simultaneous depletion of neurokinin a, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion","volume":"84","author":"Samsam","year":"2000","journal-title":"Pain"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/jpet.102.043539","article-title":"Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury","volume":"305","author":"Bang","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00726-006-0335-9","article-title":"The role of substance P in stress and anxiety responses","volume":"31","author":"Ebner","year":"2006","journal-title":"Amino Acids"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2174\/138161209788168074","article-title":"Tachykinin receptors as therapeutic targets in stress-related disorders","volume":"15","author":"Ebner","year":"2009","journal-title":"Curr Pharm Des"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1052811","DOI":"10.3389\/fneur.2023.1052811","article-title":"The role of Substance P in the defense line of the respiratory tract and neurological manifestations post COVID-19 infection","volume":"14","author":"Mehboob","year":"2023","journal-title":"Front Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"102658","DOI":"10.1016\/j.autneu.2020.102658","article-title":"Serotonin and substance P: synergy or competition in the control of breathing","volume":"225","author":"Szereda-Przestaszewska","year":"2020","journal-title":"Auton Neurosci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","article-title":"COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?","volume":"38","author":"Sarzi-Puttini","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.2174\/092986711795496746","article-title":"NK-1 receptor antagonists: a new paradigm in pharmacological therapy","volume":"18","author":"Munoz","year":"2011","journal-title":"Curr Med Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S1357-2725(01)00031-0","article-title":"Substance P","volume":"33","author":"Harrison","year":"2001","journal-title":"Biochem Cell Biol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"L831","DOI":"10.1152\/ajplung.1999.277.4.L831","article-title":"Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs","volume":"277","author":"Piedimonte","year":"1999","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","article-title":"Involvement of substance P and the NK-1 receptor in human pathology","volume":"46","author":"Mu\u00f1oz","year":"2014","journal-title":"Amino Acids"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0165-5728(02)00169-8","article-title":"Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection","volume":"129","author":"Tripp","year":"2002","journal-title":"J Neuroimmunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1023\/A:1025381803192","article-title":"Upregulation of neurokinin-1 receptor expression in the lungs of patients with sarcoidosis","volume":"23","author":"O'Connor","year":"2003","journal-title":"J Clin Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"L164","DOI":"10.1152\/ajplung.1993.265.2.L164","article-title":"Characterization of tachykinin receptors in ferret trachea by peptide agonists and nonpeptide antagonists","volume":"265","author":"Geppetti","year":"1993","journal-title":"Am J Phys Lung Cell Mol Phys"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/0091-6749(92)90138-R","article-title":"Substance P and \u03b2-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma","volume":"90","author":"Nieber","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1164\/ajrccm\/151.3_Pt_1.613","article-title":"Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis","volume":"151","author":"Tomaki","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/jme.0.0110001","article-title":"Increased tachykinin receptor gene expression in asthmatic lung and its modulation by steroids","volume":"11","author":"Adcock","year":"1993","journal-title":"J Mol Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0165-6147(96)10027-4","article-title":"Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease","volume":"17","author":"Bertrand","year":"1996","journal-title":"Trends Pharmacol Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.bjp.0703172","article-title":"Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists","volume":"129","author":"Mazzone","year":"2000","journal-title":"Br J Pharmacol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1517\/14712598.6.2.109","article-title":"G protein-coupled receptors in haematopoietic disruption","volume":"6","author":"Ramkissoon","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.2741\/1484","article-title":"Tachykinin-mediated modulation of the immune response","volume":"9","author":"Bost","year":"2004","journal-title":"Front Biosci"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jneuroim.2004.08.022","article-title":"Substance P and neurokinin-1 receptor modulation of HIV","volume":"157","author":"Ho","year":"2004","journal-title":"J Neuroimmunol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","article-title":"Neuropeptide substance P and the immune response","volume":"73","author":"Mashaghi","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fncel.2016.00296","article-title":"The therapeutic potential of targeting substance P\/NK-1R interactions in inflammatory CNS disorders","volume":"10","author":"Johnson","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jcp.20061","article-title":"The role of substance P in inflammatory disease","volume":"201","author":"O\u2019Connor","year":"2004","journal-title":"J Cell Physiol"},{"key":"ref52","first-page":"247","article-title":"Substance P receptor mediated macrophage responses","volume-title":"Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases","author":"Marriott","year":"2001"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1006\/cimm.1998.1248","article-title":"Substance P diminishes lipopolysaccharide and interferon-\u03b3-induced TGF-\u03b21 production by cultured murine macrophages","volume":"183","author":"Marriott","year":"1998","journal-title":"Cell Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1365-2249.1994.tb06039.x","article-title":"Disturbed immunoregulatory properties of the neuropeptide substance P on lymphocyte proliferation in HIV infection","volume":"96","author":"Covas","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4049\/jimmunol.165.1.182","article-title":"IL-4 and IFN-\u03b3 up-regulate substance P receptor expression in murine peritoneal macrophages","volume":"165","author":"Marriott","year":"2000","journal-title":"J Immunol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","article-title":"Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia","volume":"11","author":"Leng","year":"2020","journal-title":"Aging Dis"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/mds.29433","article-title":"Olfactory neuron Substance P is overexpressed in Parkinson's disease reflecting gut dysfunction","volume":"38","author":"Schirinzi","year":"2023","journal-title":"Mov Disord"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/mds.28824","article-title":"Serum Substance P is increased in Parkinson's disease and correlates with motor impairment","volume":"37","author":"Schirinzi","year":"2022","journal-title":"Mov Disord"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.bbi.2022.12.017","article-title":"Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction","volume":"108","author":"Schirinzi","year":"2023","journal-title":"Brain Behav Immun"},{"key":"ref60","volume-title":"Ar\u2019ernaya funktsiya legkikh i obespechenie gomeostaza (barrier function of lungs and homeostasis)","author":"Dubilei","year":"1987"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14728222.2020.1783243","article-title":"The cyto kine storm of COVID-19: a spotlight on prevention and protection","volume":"24","author":"Pearce","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"112159","DOI":"10.1016\/j.biopha.2021.112159","article-title":"Neurokinin-1 receptor as a potential drug target for COVID-19 treatment","volume":"143","author":"Mehboob","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fneur.2023.1210194","article-title":"Role of endothelial cells and angiotensin converting enzyme-II in COVID-19 and brain damages post-infection","volume":"14","author":"Mehboob","year":"2023","journal-title":"Front Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1134\/S2079086421060049","article-title":"Damage to the vascular endothelium as a leading mechanism of COVID-19 systemic pathology","volume":"11","author":"Gomazkov","year":"2021","journal-title":"Biol Bull Rev"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.3390\/ijms222111920","article-title":"The role of endothelium in COVID-19","volume":"22","author":"Ionescu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref66","author":"Virchow","year":"1858"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel an giotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human ho molog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive car boxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-con verting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel corona virus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11684-020-0754-0","article-title":"The single-cell RNA-seq data analysis o0n the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection","volume":"14","author":"Zou","year":"2020","journal-title":"Front Med"},{"key":"ref72","article-title":"substance P","author":"Graefe","year":"2020","journal-title":"Biochemistry"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/sj.bjp.0703173","article-title":"Respiratory actions of tachykinins in the nucleus of the solitary tract: effect of neonatal capsaicin pretreatment","volume":"129","author":"Mazzone","year":"2000","journal-title":"Br J Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.3390\/ijms21228612","article-title":"The rationale for angiotensin receptor neprilysin inhibitors in a multi-targeted therapeutic approach to COVID-19","volume":"21","author":"Bellis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"115908","DOI":"10.1016\/j.ejmech.2023.115908","article-title":"Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: a promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection","volume":"263","author":"Mei","year":"2024","journal-title":"Eur J Med Chem"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3892\/etm.2023.12340","article-title":"Comprehensive analysis and immunohistochemistry localization of NRP1 expression in pancancer and normal individual tissues in relation to SARS-CoV-2 susceptibility","volume":"27","author":"Fu","year":"2023","journal-title":"Exp Ther Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"ref78","first-page":"426","article-title":"Neurokinin 1 receptor antagonist along with dexamethasone reduces the inflammation in COVID-19 patients: a novel therapeutic approach","volume":"10","author":"Mehboob","year":"2023","journal-title":"Adv Life Sci"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/pathogens11111256","article-title":"Neuro\u2013immune interactions in severe COVID-19 infection","volume":"11","author":"Rossi","year":"2022","journal-title":"Pathogens"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","article-title":"The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug","volume":"28","author":"Mu\u00f1oz","year":"2010","journal-title":"Investig New Drugs"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19-preliminary report","volume":"384","author":"Chappell","year":"2021","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1161\/01.HYP.0000185148.27901.fe","article-title":"Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat","volume":"46","author":"Rivi\u00e8re","year":"2005","journal-title":"Hypertension"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jcf.2004.06.006","article-title":"Cytokines and inflammatory mediators in cystic fibrosis","volume":"3","author":"Courtney","year":"2004","journal-title":"J Cyst Fibros"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S4385","article-title":"Inflammatory mechanisms in the lung","volume":"2","author":"Moldoveanu","year":"2008","journal-title":"J Inflamm Res"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume":"318","author":"South","year":"2020","journal-title":"Am J Phys Heart Circ Phys"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin\u2013angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"m406","DOI":"10.1136\/bmj.m406","article-title":"COVID-19 induced renin\u2013angiotensin system (RAS) imbalance may drive acute lung injury: the evidence and therapeutic options","volume":"368","author":"Henry","year":"2020","journal-title":"Br Med J"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2016.11.064","article-title":"Roles of angiotensin peptides and recombinant human ACE2 in heart failure","volume":"69","author":"Basu","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Biomed Cent"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1007\/s00018-007-6228-6","article-title":"Angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"64","author":"Imai","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"19840","DOI":"10.1038\/srep19840","article-title":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3390\/vaccines10071045","article-title":"The associations between cytokine levels, kidney and heart function biomarkers, and expression levels of angiotensin-converting Enzyme-2 and Neuropilin-1 in COVID-19 patients","volume":"10","author":"Sultan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"ref96","volume-title":"Probleme der Peptidforschung Akademie-Verlag Berlin 1987","author":"Aktuelle","year":"2022"},{"key":"ref97","author":"Oehme","year":"2022"},{"key":"ref98","author":"Jentzsch","year":"1992"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/brainsci11040454","article-title":"Long-term brain disorders in post Covid-19 neurological syndrome (PCNS) patient","volume":"11","author":"Nuzzo","year":"2021","journal-title":"Brain Sci"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3390\/jcm10091947","article-title":"Post-acute COVID-19 neurological syndrome: a new medical challenge","volume":"10","author":"Nuzzo","year":"2021","journal-title":"J Clin Med"},{"key":"ref101","first-page":"108151","article-title":"COVID-19 and diabetes management: What should be considered?","author":"Ceriello","year":"2020"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/met.2020.0037","article-title":"Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management","volume":"18","author":"Stoian","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.ajpc.2020.100009","article-title":"Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: a scientific statement from the American Society for Preventive Cardiology","volume":"1","author":"Khera","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"ref104","first-page":"55","article-title":"Rudolf Virchow & Hermann von Helmholtz: ihr Wirken in und f\u00fcr Berlin - Impulse f\u00fcr die Gesundheitsstadt Berlin","volume":"73","author":"Oehme","year":"2022","journal-title":"Berlin"},{"key":"ref105","first-page":"213","article-title":"Die bakteriologische und die molekulare Transition der Medizin: Historizit\u00e4t und Kontingenz als Erkenntnismittel","volume":"54","author":"Labisch","year":"2004","journal-title":"Sudhoffs Archiv Beihefte"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1370454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T04:49:35Z","timestamp":1717044575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1370454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":105,"alternative-id":["10.3389\/fneur.2024.1370454"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1370454","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1370454"}}